Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

51.60USD
11:46am EDT
Change (% chg)

$0.65 (+1.28%)
Prev Close
$50.95
Open
$51.25
Day's High
$51.60
Day's Low
$50.30
Volume
32,911
Avg. Vol
258,426
52-wk High
$136.90
52-wk Low
$50.30

Select another date:

Wed, May 9 2018

BRIEF-Puma Biotechnology Q1 Loss Per Share $0.65

* PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib

* PUMA BIOTECHNOLOGY SAYS ‍GIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB Source text for Eikon: (http://bit.ly/2G6kIc2) Further company coverage:

BRIEF-Puma Biotechnology Inc Files For Non Timely 10-K - SEC Filing‍​

* PUMA BIOTECHNOLOGY INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text: (http://bit.ly/2F6s3qK) Further company coverage:

BRIEF-Puma Biotechnology Q4 Loss Per Share $1.71

* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​

* EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

Select another date: